Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.

نویسندگان

  • Stephen P Fink
  • Dawn M Dawson
  • Yongyou Zhang
  • Adam Kresak
  • Earl G Lawrence
  • Peiying Yang
  • Yanwen Chen
  • Jill S Barnholtz-Sloan
  • Joseph E Willis
  • Levy Kopelovich
  • Sanford D Markowitz
چکیده

Non-steroidal anti-inflammatory drugs prevent colorectal cancer by inhibiting cyclooxygenase (COX) enzymes that synthesize tumor-promoting prostaglandins. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a tumor suppressor that degrades tumor-promoting prostaglandins. Murine knockout of 15-PGDH increases susceptibility to azoxymethane-induced colon tumors. It also renders these mice resistant to celecoxib, a selective inhibitor of inducible COX-2 during colon neoplasia. Similarly, humans with low colonic 15-PGDH are also resistant to colon adenoma prevention with celecoxib. Here, we used aspirin and sulindac, which inhibit both COX-1 and COX-2, in order to determine if these broader COX inhibitors can prevent colon tumors in 15-PGDH knockout (KO) mice. Unlike celecoxib, sulindac proved highly effective in colon tumor prevention of 15-PGDH KO mice. Significantly, however, aspirin demonstrated no effect on colon tumor incidence in either 15-PGDH wild-type or KO mice, despite a comparable reduction in colonic mucosal Prostaglandin E₂ (PGE₂) levels by both sulindac and aspirin. Notably, colon tumor prevention activity by sulindac was accompanied by a marked induction of lymphoid aggregates and proximal colonic inflammatory mass lesions, a side effect seen to a lesser degree with celecoxib, but not with aspirin. These findings suggest that sulindac may be the most effective agent for colon cancer prevention in humans with low 15-PGDH, but its use may also be associated with inflammatory lesions in the colon.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.

Pharmacologic inhibitors of the prostaglandin-synthesizing COX-2 oncogene prevent the development of premalignant human colon adenomas. However, resistance to treatment is common. In this study, we show that the adenoma prevention activity of the COX-2 inhibitor celecoxib requires the concomitant presence of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) tumor suppressor gene, and that los...

متن کامل

Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.

PURPOSE Nonsteroidal anti-inflammatory drugs (NSAID) are promising chemopreventive agents against colon and other cancers. However, the molecular basis mediated by NSAIDs for chemoprevention has not been fully elucidated. Environmental carcinogens induce DNA mutation and cellular transformation; therefore, we examined the effect of NSAIDs on carcinogenesis mediated by the aryl hydrocarbon recep...

متن کامل

Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention.

Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NO-NSAIDs), consisting of a known nonsteroidal anti-inflammatory drug (NSAID) and a nitric oxide (NO)-releasing group, are reported safer than NSAIDS: To assess their potential in colon cancer chemoprevention, we studied in vitro the effect of NO-aspirin, NO-sulindac, and NO-ibuprofen on colonocyte kinetics. These three NO-NSAIDs redu...

متن کامل

Phase I Trial of Sulindac plus 5-Fluorouracil and Levamisole: Potential Adjuvant Therapy for Colon Carcinoma

I N T R O D U C T I O N Adjuvant chemotherapy with 5-FU 2 and levamisole was shown to significantly improve survival rates in patients with resected lymph node-positive (stage III) colon carcinomas (1). Attempts to improve on these results are being actively pursued. Epidemiological (2-7), clinical (8-12), and laboratory (13-19) studies indicate that NSAIDs, including sulindac, may reduce color...

متن کامل

Phase I Trial of Sulindac plus 5-Fluorouracil and Levamisole: Potential Adjuvant Therapy for Colon Carcinoma

I N T R O D U C T I O N Adjuvant chemotherapy with 5-FU 2 and levamisole was shown to significantly improve survival rates in patients with resected lymph node-positive (stage III) colon carcinomas (1). Attempts to improve on these results are being actively pursued. Epidemiological (2-7), clinical (8-12), and laboratory (13-19) studies indicate that NSAIDs, including sulindac, may reduce color...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Carcinogenesis

دوره 36 2  شماره 

صفحات  -

تاریخ انتشار 2015